Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
WILLOW ANNOUNCES INITIATION OF STRATEGIC REVIEW PROCESS
SUNNYVALE, Calif. , Jan. 20, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces that it has initiated a formal strategic review process to identify, assess and evaluate a broad range of potential strategic alternatives.» Mehr auf prnewswire.com
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Company reports record revenue of $1.7 million in Q3 Company announced a partnership in the high growth biopesticides sector that is expected to generate over $2 million in revenue in its first year Company closed a brokered financing for aggregate gross proceeds of $1.6 million Company signed a royalty agreement with Kalsec that includes milestone payments and tiered royalty payments on net worldwide sales after launch Company signed a second program with a global ingredient manufacturer to develop an enzyme for a large volume API and in November successfully completed its first program with the partner Willow increasing its 2024 revenue guidance for the year to over $4.5 million SUNNYVALE, Calif. , Nov. 12, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, announces third quarter financial results and provides a corporate update.» Mehr auf prnewswire.com
WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO
SUNNYVALE, Calif. , Nov. 7, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, announces that it has partnered a high value ingredient from its internal portfolio with a global ingredient manufacturer to fully develop, scale, and commercialize.» Mehr auf prnewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | Sep. 2024 | |
---|---|---|
Umsatz | 1,13 Mio | 141,31% |
Bruttoeinkommen | 1,13 Mio | 1.302,12% |
Nettoeinkommen | −827,11k | 46,66% |
EBITDA | −474,62k | 59,38% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 3,71 Mio€ |
Anzahl Aktien | 144,85 Mio |
52 Wochen-Hoch/Tief | 0,0916€ - 0,0119€ |
Dividenden | Nein |
Beta | 0,94 |
KGV (PE Ratio) | −0,64 |
KGWV (PEG Ratio) | −0,05 |
KBV (PB Ratio) | 25,33 |
KUV (PS Ratio) | 1,77 |
Unternehmensprofil
Willow Biosciences Inc. ist ein Biotechnologieunternehmen, das in Kanada pflanzliche Inhaltsstoffe für die Konsumgüter-, Lebensmittel- und Getränkeindustrie sowie für pharmazeutische Produkte entwickelt, produziert und verkauft. Das Unternehmen produziert auch Cannabidiol, Cannabigerol und Varin-Cannabinoide, wie Cannabigerovarin, Cannabidivarin und Tetrahydrocannabivarin. Willow Biosciences Inc. wurde 1981 gegründet und hat seinen Hauptsitz in Calgary, Kanada.
Name | Willow Biosciences |
CEO | Dr. Chris Savile |
Sitz | Calgary, ab Kanada |
Website | |
Börsengang | |
Mitarbeiter | 19 |
Ticker Symbole
Börse | Symbol |
---|---|
Pnk | CANSF |
Toronto Stock Exchange | WLLW.TO |
Frankfurt | 3D7.F |
Assets entdecken
Shareholder von Willow Biosciences investieren auch in folgende Assets